Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

RxSight (RXST) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to 31.77%.

  • RxSight's EBITDA Margin fell 156300.0% to 31.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.47%, marking a year-over-year decrease of 20000.0%. This contributed to the annual value of 19.5% for FY2024, which is 349700.0% up from last year.
  • Per RxSight's latest filing, its EBITDA Margin stood at 31.77% for Q3 2025, which was down 156300.0% from 35.43% recorded in Q2 2025.
  • RxSight's 5-year EBITDA Margin high stood at 15.65% for Q4 2024, and its period low was 275.27% during Q2 2021.
  • Over the past 5 years, RxSight's median EBITDA Margin value was 66.64% (recorded in 2023), while the average stood at 97.42%.
  • Over the last 5 years, RxSight's EBITDA Margin had its largest YoY gain of 2048100bps in 2021, and its largest YoY loss of -9541100bps in 2021.
  • Over the past 5 years, RxSight's EBITDA Margin (Quarter) stood at 186.84% in 2021, then soared by 48bps to 96.76% in 2022, then skyrocketed by 67bps to 31.92% in 2023, then soared by 51bps to 15.65% in 2024, then crashed by -103bps to 31.77% in 2025.
  • Its EBITDA Margin was 31.77% in Q3 2025, compared to 35.43% in Q2 2025 and 22.01% in Q1 2025.